Brief: Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute

04/02/2025 14:22

Feb 4 (Reuters) - Rezolute Inc  RZLT.O :
    * REZOLUTE PROVIDES UPDATE ON ITS PHASE 3 SUNRIZE STUDY OF
ERSODETUG FOR THE TREATMENT OF HYPOGLYCEMIA DUE TO CONGENITAL
HYPERINSULINISM
    * REZOLUTE INC - SUNRIZE ENROLLMENT COMPLETION EXPECTED IN
Q2 2025
    * REZOLUTE INC - DMC REVIEWED OPEN-LABEL ARM FOR INFANTS,
TARGET
DRUG CONCENTRATIONS SAFELY REACHED
    * REZOLUTE INC - DMC APPROVES INFANT ENROLLMENT INTO
DOUBLE-BLIND
STUDY

Source text:  ID:nGNX9dD3TS 
Further company coverage:  RZLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))